

15

IN LIVER ENDOCRINE &
LIVER

10

IN GENDER AFFIRMING
SURGERY & FOCAL
ABLATION

10

IN NIH FUNDING
FOR UROLOGY

Contents

1 MESSAGE FROM THE CHAIR

2 FACTS & FIGURES

4 2017 IN BRIEF

10 2017 IN DEPTH

11 Advanced Bladder Cancer

12 Prostate Cancer: Quality of Life

14 Prostate Cancer: Active Surveillance

16 Reconstructive Urological Surgery

18 Incontinence

20 Complex Pediatric Case: Antenatal Hydronephrosis

22 ACADEMIC ACTIVIT

25 FACULT

26 LEADERSHIP

 On the cover: Immunofluorescent light micrograph of cancer cells of the human bladder, stopped in the process of rapid cell division

is past year, we passed the 15-year mark in collecting data for our radical prostatectomy prospective database, the longest continuously collected database, capturing both survival and quality of life outcomes. Begun just after the turn of the millennium and now with more than 2,000 men enrolled, the database continues to provide insights on long-term outcomes following this procedure, insights that are highly relevant because functional outcomes, such as continence, sexual function, and lower urinary tract symptoms, are also affected by aging. In 2017, our long-term data provided encouraging news for men who are considering or who have had radical prostatectomy to treat lower ur

10+


B E C A E

Prioritizing
Detection

NYU Langone Health



Building on Existing Programs and Forging New Ground



Understanding Bladder Cancer in Molecular Detail

NYU Langone Health's urology research program is leading a major effort to better understand and treat bladder cancer. Its five-year, \$8.2 million National Cancer Institute program

Advancing Science, Improving Assessment for Men at Risk of Prostate Cancer

Urologist Samir S. Taneja, MD, and radiologist Andrew B. Rosenkrantz, MD, established MRI image-guided biopsy as a valuable tool in identifying potentially cancerous lesions in the prostate and then led a select expert panel in developing consensus about its use in repeat biopsy. Dr. Taneja and Dr. Rosenkrantz were the lead authors of the AUA (American Urological Association) and SAR (Society of Abdominal Radiology) Prostate Joint Panel Consensus Statement, which appeared in the December 2016 issue of the *Journal of Urology*.

Save the Date: Continuing Medical Education

A C 23 24, 2018

Update in Female Pelvic Medicine
and Reconstructive Surgery



E 15 16, 2018

Advances in Screening, Detection,
and Treatment of Prostate Cancer

**AUA Recognition for National
Leadership in Gender-Conforming**

Reducing Unnecessary Risk for Women Undergoing Pelvic Procedures

Surgery for pelvic organ prolapse (POP) is twice as common as surgery for incontinence, but dual procedures are often performed.

After the FDA issued a Public Health Notification about use of transvaginal mesh, many women became wary of mesh placement procedures. A recent comparison by NYU Langone Health female pelvic medicine specialists noted that the number of patients choosing to undergo midurethral sling placement at the time of POP repair fell after the FDA notification. Yet, the postoperative incidence of urethral bulking

Expanding Urology Services in Brooklyn


ED A C G G ACE . A G E
A ' B EA

Grace S. Hyun, MD, has joined NYU Langone Health as clinical associate professor of urology and chief of Pediatric Urology at NYU Langone Hospital—Brooklyn. Dr. Hyun, who previously served as associate director of Pediatric Urology at Mount Sinai Medical Center, brings expertise in all aspects of pediatric urology, including treatment and

management of varicoceles, undescended testicles, hypospadias, kidney stones, and congenital anomalies of the kidneys and urinary tract (e.g., ureteropelvic junction obstruction, vesicoureteral reflux, and ureterocele), in collaboration with NYU Langone Health's highly experienced pediatric nephrology team, which also offers minimally invasive surgery.

Dr. Hyun received her doctor of medicine degree from Harvard Medical School in 2004 and completed her urology residency at Mount Sinai Medical Center in 2008. She completed her pediatric urology fellowship at Children's Hospital of Philadelphia. Dr. Hyun

will be joining the urology department at NYU Langone Hospital—Brooklyn in September 2014.



E-C GA E E A E EB ADDE F CA CE



A

Prostate Cancer: Men Living Longer, Maintaining Quality of Life



A C E CE A EAF E
 AD CA A EC
 A E GE E A AG G 10G 216 GE -21.3 25 104.7 15 5 25.36 0.0 0.7 .4 -1.1. 265 54 55 0 2.3 25.3 55-25.1 56 111 -1.8 50.6 10 54

Active Surveillance a Safe Option for Men with Low-Risk Prostate Cancer



published online in *Journal of Clinical Oncology* in October 2016, reported an increase from

h t t p : / / d o i . o r g / 1 0 . 1 2 0 0 / j c o . 2 0 1 6 . 1 6 . 1 e . 1

Dr. Loeb (A) -

Along with an international research team from Sweden and England, Dr. Loeb, assistant professor of urology and population health and a member of Perlmutter Cancer Center, evaluated data

from Sweden's National Prostate Cancer Registry, one of only a few national databases in the world. The researchers found that Swedish men with very-low-risk cancer are more likely to choose AS when presented with the choice between AS and immediate treatment. The study,

G E EA E F
-AGG E ED EA E

Innovations Reduce Complications in Reconstructive Urological Surgery



Lee C. Zhao, MD, assistant professor of urology, director of Male Reconstructive Surgery, pioneered the world's first gender-affirming robot-assisted surgical procedures, using the da Vinci® Surgical System in NYU Langone's Robotic Surgery Center.




Dr. Zhao's recent innovations in both female-to-male and male-to-female surgeries help avoid common urological complications such as urethral strictures and fistulas. In 2017, Dr. Zhao presented the results of two of these procedures.

The first procedure, for those undergoing a female-to-male transition, is a robot-assisted laparoscopic transabdominal approach to neophallus construction, which allows the individual to void while standing. The surgery, which lengthens the urethra and provides supporting muscle, was performed without urethral complications in 11 transgender men from mid-2016 to mid-2017. Dr. Zhao presented this development at the Sexual Medicine Society of North America Fall 2017 Scientific Meeting in San Antonio, Texas.

Separately, for those undergoing a male-to-female transition, Dr. Zhao developed a robot-assisted technique for

the dissection of the perineum and the creation of a neovaginal canal—one of the most challenging aspects of penile inversion vaginoplasty (PiV). Dr. Zhao presented the outcomes for 15 transgender women who underwent PiV at NYU Langone at the 2017 American Urological Association (AUA) annual meeting in Boston, Massachusetts. The complex, four- to six-hour procedure requires mobilization of tissue flaps or abdominoplasty and skin graft harvest.

The technique achieved desired vaginal length in a reproducible manner, with only two patients experiencing postsurgical complications that required additional treatment.



EE GA AC E FFE
G EA E A A A DC

Improving Outcomes for People with Incontinence




D E EA CA A E
C CA BA E
C E CECA EA G E
C E A E

Although most multiple sclerosis (MS) patients report that urinary problems interfere with their lives, many do not seek urologic care—and little analysis has been done to date to learn why. A new study led by NYU Langone Health urologists sheds light on one critical barrier to urology

referrir9cn4.9 (: a l)-14.4 (a)-2.5 (c)-17.7 (k8 (d)-215 (l)-4.3 18)0.8 (ne H)m-34.8 (ri(r)-9.7 A17.7 (k8 (d.7 (o)-9.n7 (o)39.5 (l8b)-7.6 (a)-36.-5.3 (n)-1.1 (t)1)-13.3
tl bar fs s2 (5 l)-14.4TJTtu-1.333 T6.-5.3 (n)-1.1 (t)1artr31626.3 (r)9mis, m9mri9cn4.9 (: a l)-14.4molfYadori5156 f(e)-d9cn4(y)-10 (.333 w (n)-9.8e1 .333 TD

Antenatal Hydronephrosis: Benign Finding or Congenital Anomaly of the Kidney and Urinary Tract?



()1 11.01 13 2 -1304(-)2 - 5312.(())3.4(2)-1141(2)14-1(0: 52.)15 01)23.22)-10 (0.)-3.4-0-1022- 21 . . .01_32. 0)-5213.27) .1 ()-21.



(A 3),

CA E2: GE DE A ED AF E
E E , B E E
E F D E

A 31- 4-15.5 ()21 . ()-11. 23 ()-100(,)3 .23-2.4 ()-2. (()2.3 ()-15 ()-10 ())-333 . ()-1 ()- .2 ()-1 3(4)-12.2

E EC B CA

Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer

Loeb S, Roupert M, Van Oort I, N'dow J, Van Gorp M, Bloemberg J, Darraugh JA, Ribal M. Novel use of twitter to disseminate and evaluate adherence with clinical guidelines by the European Association of Urology. *2017 Jun*;119(6):820-822.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. *2017 Jul*;120(1):61-68.

Loeb S, Stattin P. Further evidence against a causal association between erectile dysfunction drugs and melanomas. *Nov*;70(5):816-817.

Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight CJ, Borgmann H. Tweet this: How advocacy for breast and prostate cancers stacks up on social media. *2017*;120(4):461-463.

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. *2017*;109(8).

Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. How active is active surveillance? intensity of follow-up during active surveillance for prostate cancer in the United States. *2016*;196(3):721-726.

Loeb S. Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era. *2017 Jul*;120(1):3-4.

Loeb S. Evidence-based versus personalized prostate cancer screening: using baseline prostate-specific antigen measurements to individualize screening. *2016 Aug 10*;34(23):2684-2686.

Loeb S. Repeat Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. *2017 Jul 4*. [Epub ahead of print]

Loeb S. When is a negative prostate biopsy really negative? Repeat biopsies in detection and active surveillance. *Apr*;197(4):973-974.

Loeb S. Will changes to prostate cancer screening guidelines preserve benefits and reduce harms? *2017 Jan*;71(1):66-67.

Madka V, Mohammed A, Li Q, Zhang Y, Biddick L, Patlolla JM, Lightfoot S, Towner RA, Wu XR, Steele VE, Kopelovich L, Rao CV. Targeting mTOR and p53 signaling inhibits muscle invasive bladder cancer in vivo. *2016*;9(1):53-62.

Makarov DV, Chrouser K, Gore JL, Maranchie J, Nielsen ME, Saigal C, Tessier C, Fagerlin A. AUA White Paper on implementation of shared decision making into urological practice. *2016 Sep 01*;3(5)355-363.

Makarov DV, Holmes-Rovner M, Rovner D, Averch T, Barry MJ, Chrouser K, Gee WF, Goodrich K, Haynes M, Krahn M, Saigal C, Sox HC, Stacey D, Tessier C, Waterhouse RL,

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. *J Clin Oncol*. 2017;35(8):1085-1093.

Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH. Use of Twitter to facilitate sharing of clinical expertise in urology. *J Urol*. 2017 Jun 7. [Epub ahead of print]

Stone BV, Cohn MR, Donin NM, Schulster M, Wysock JS, Makarov DV, Bjurlin MA. Evaluation of unplanned hospital readmissions after major urologic inpatient surgery in the era of accountable care. *J Urol*. 2017 Nov;198:94-100.

Talenfeld A, Atoria C, Kwan S, Durack J, Huang W, Elkin E. Percutaneous ablation versus surgery for small renal cancers: A population-based analysis. *Urology*. 2016;27(3):S31-S32.

Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M. Final results of a phase III multicenter trial of sipuleucel-S. *J Clin Oncol*. 2016;34(12):1382-1390.

ca.3 (e)-(, R)-23 (e)-1848ageu1.1 (o)-21.9.7 (k)-62 (1.9 (e)- (1)65 (])TJ/e)-27.88.7 2 (c)-312 (U)3 (t)-5337.2 (it.9.7(, R)-2239. (u12 (St10.5 (u)at.9.7(, R)-223(n)-1294)-51.5 a)-47.2 (r)-21.65.7 (-)14(t)5610 1 TfJ U)29.5 (r.4 (6R)-32

Herbert Lepor, MD

Leadership

Kenneth G. Langone
Chair, Board of Trustees

Robert I. Grossman, MD
Saul J. Farber Dean and
Chief Executive Officer

Steven B. Abramson, MD
Senior Vice President and
Vice Dean for Education, Faculty,
and Academic Affairs
Senior Vice President and

and Aca34Eh58.9 [(S)5 (n)-8Nad A4-19.9(d(S)-20.1 (a)-40.1 (i)-37.3 (O)-27.5 (s)]TJ0.137 0.123 0.126 scn/GS0 gs/T12 1 Tf0.003 Tc -0.013 Tf0 -2.125 TDD)-24.6a.eia-34.2 (-20.5,

